Court decisions last week in the U.S. related to patent infringement litigation between MorphoSys AG and Cambridge Antibody Technology Group plc leave nothing resolved, although they do place all three suits between the parties in the same court. And while a preliminary ruling in the "Griffiths" patent suit appeared to favor MOR, CAT said its freedom to operate is not in jeopardy.

Last week's action in the U.S. District Court for the District of Columbia involved a suit filed by MOR (Munich, Germany), which is seeking a determination that it does not infringe the "Griffiths" patent (U.S. Patent No. 5,885,793) held by CAT, and that the patent is invalid. The Griffiths patent relates to a method for obtaining antibodies to specific human self antigens through the use of phage display libraries.